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The molecular mechanisms that regulate functional activation of IL-1a remain elusive. In this issue of Immu-
nity, Zheng et al. (2013) describe a molecular system implicating interleukin-1 receptor-2 (IL-1R2) as a prin-
cipal cytosolic factor that controls functional IL-1a activation during necrosis.Inflammation is a coordinated physiolog-
ical host response to cell damage, stress,
or infection. In the context of ‘‘sterile
inflammation,’’ a response to cell damage
or stress in the absence of pathogens,
inflammation is triggered by host-derived
factors, called danger-associated molec-
ular patterns (DAMPs), that are released
from damaged cells and signal distur-
bances of cellular or tissue homeostasis.
The principal goal of the inflammatory
response to DAMPs is restoration of
physiological homeostasis through tissue
repair. When cell damage or stress asso-
ciates with the presence of or are directly
induced by pathogens, the inflammatory
response can be triggered by pathogen-
associated molecular patterns (PAMPs).
The goals of the host response to PAMPs
are pathogen elimination and establish-
ment of immunity. The interleukin-1 (IL-1)
family cytokines IL-1a and IL-1b are
among the most potent host proteins
that activate inflammatory responses to
both DAMPs and PAMPs (Dinarello,
2009). Upon engagement of the IL-1
receptor type 1 (IL-1R1), IL-1a and IL-1b
initiate identical biological responses
through a signaling cascade that conveys
themessage that the cellular homeostasis
has been disturbed and that the recruit-
ment of specialized cells to initiate tissue
repair and/or pathogen elimination is
warranted.
Apart from being synthesized as pre-
cursor proproteins and engaging the
same receptor at the plasma membrane,
the similarity between IL-1a and IL-1b is
limited. Extensive efforts in trying to
understand molecular processes that
lead to functional activation of IL-1b
have resulted in a cohesive model of
initiation of inflammation via caspase-1-
dependent proteolytic processing of pro-IL-1b and secretion of its mature form
from the cell, where the mature p17 IL-
1b form is the only biologically active
form of this cytokine (Dinarello, 2009).
The caspase-1-dependent processing
of pro-IL-1b is tightly controlled by the
inflammasome—a supramolecular com-
plex of cytosolic proteins that sense the
presence of noxious toxins or pathogen
components, and, when prompted, multi-
merize and activate caspase-1 (Schroder
and Tschopp, 2010). Caspase-1, how-
ever, appears to play no role in proteolytic
processing of pro-IL-1a, but rather
controls its secretion from the cell via a still
poorly defined mechanism (Gross et al.,
2012; Kuida et al., 1995). Importantly,
and in contrast to IL-1b, both the pro-IL-
1a p33 form and its mature p17 IL-1a
forms are the functional biologically active
ligands for IL-1R1 (Mosley et al., 1987),
implying that inflammation can be initi-
ated by IL-1a in various pathological
contexts independently of its proteolytic
processing. Although secretion of IL-1b
is thought to activate systemic inflamma-
tory responses, IL-1a can function both as
a secreted and as a membrane-bound
cytokine and, thus, trigger and sustain
inflammation locally. To this end, IL-1a
has been shown to be the principal
inducer of inflammation in response to
dying and necrotic cells, where the loss
of plasma membrane integrity leads to a
passive release of IL-1a-containing cyto-
solic content to the surrounding milieu
and initiation of proinflammatory signaling
downstream of IL-1R1 (Chen et al., 2007).
Because IL-1a is expressed ubiqui-
tously (Dinarello, 2009), these observa-
tions imply that the necrotic death of
any cell type in the body should neces-
sarily induce potent local inflammatory
responses irrespective of the cell andImmunity 38,tissue type. This, however, may not be
beneficial to the host under all physiolog-
ical or pathophysiological circumstances.
Exacerbated cell necrosis-driven inflam-
mation in tissues with limited regenerative
capacity (for instance, in kidneys or heart)
can lead to organ dysfunction or even
death. But what can prevent pro-IL-1a
from initiating inflammation in response
to cellular necrosis, which is, in many
cases, an uncontrolled process of cata-
strophic cell demise?
In this issue of Immunity, Zheng et al.
(2013) have revealed an elaborate and
elegant molecular system that controls
pro-IL-1a biological activity postnecrosis.
They implicate a decoy IL-1R type II
(IL-1R2) as a key protein that binds pro-
IL-1a in the cytosol and prevents its inter-
action with IL-1R1 upon release from
necrotic cells. Initial observations that
Zheng et al. (2013) made have shown
that IL-1R1 signaling in response to
necrotic cells is highly cell type depen-
dent. They found that although primary
human monocyte-derived macrophages,
aortic vascular smooth muscle cells
(VSMCs), and immortalized Jurkat and
HeLa cells expressed similar amounts of
pro-IL-1a, upon triggering necrosis, only
cytosolic content from VSMCs and not
other cell types was able to initiate IL-
1R1-dependent responses. Furthermore,
the authors found that in necrotic VSMCs,
the pro-IL-1a p33 form was readily
proteolytically processed to its mature
p17 IL-1a form by calpains (Kobayashi
et al., 1990) and that this processing did
not occur upon induction of necrosis in
other cell types that they analyzed. The
authors posited that a cytosolic factor
may exist that associates with pre-IL-1a
in ‘‘noninflammatory’’ necrotic cell types
that blocks both the pro-IL-1amaturationFebruary 21, 2013 ª2013 Elsevier Inc. 203
Figure 1. The Model of IL-1R2-Dependent Control of IL-1a
Activation
IL-1a is synthesized as a proprotein p33 form that is sequestered in the cytosol
by IL-1R2. While in complex with IL-1R2, the maturation of pro-IL-1a through
proteolytic processing with cellular proteases, including calpain, elastase,
Granzyme B, or chymase, is blocked. Upon loss of the plasma membrane
integrity (depicted as blebs surrounding the cell) during necrosis, the release
from cells of pro-IL-1a:IL-1R2 complexes cannot activate IL-1R1 signaling.
However, after inflammasome activation, caspase-1 can cleave IL-1R2 (1)
and liberate pro-IL-1a (2), which now becomes available for proteolytic pro-
cessing by calpains (3), giving rise to a highly biologically active IL-1a p17
form. Necrosis induction in cells that express pro-IL-1a but lack IL-1R2 will
lead to the release of both pro- and mature IL-1a forms, which will activate
inflammatory responses via IL-1R1. The mature IL-1a p17 form is a more
potent ligand for IL-1R1 than the p33 pre-IL-1a form, and its release triggers
stronger biological responses.
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interact with IL-1R1.
Although an association of
pro-IL-1a with IL-1R2 in the
cytosol has been previously
reported (Kawaguchi et al.,
2006), the role of this interac-
tion in regulating inflamma-
tion to necrotic cells was not
revealed until now. Further-
more, it still remains contro-
versial whether proteolytic
processing of pro-IL-1a is
ultimately required for its func-
tional activation or whether
both the p33 pro-IL-1a and
its mature p17 forms are
equally potent at inducing
IL-1R1-dependent inflam-
matory responses. Among
the reasons that prevented
definitive resolution of this
question was a poor solu-
bility of recombinant p33
pro-IL-1a form, which com-
plicated comparative anal-
yses of biological activities
of the two IL-1a forms.
To address this question,
Zheng et al. (2013) ex-
pressed two variants of
p33 pre-IL-1a, one as a
His-tagged form and the
other conjugated with GST.
Through extensive sets ofanalyses, the authors demonstrated
that calpain-dependent processing sig-
nificantly increased biological activity
of IL-1a. Furthermore, by using an
IL-1 receptor antagonist (IL-1RA) com-
petition approach to evaluate the rela-
tive affinity of the p33 and p17 IL-1a
forms to IL-1R1, the authors concluded
that the mature p17 IL-1a form was
more efficient at binding IL-1R1 and
was 46.3-fold more physiologically
active than its p33 pre-IL-1a form.
Although these data are in line with
recent findings by Afonina et al.
(2011), who demonstrated that pro-IL-
1a proteolysis with Granzyme B,
calpain, and elastase significantly en-
hances its biological activity, the ulti-
mate answer to the question on
whether pro-IL-1a is a potent biologi-
cally active ligand for IL-1R1 could
come from analyzing inflammatory
responses to necrotic IL-1a-deficient
VSMCs that have been reconstituted204 Immunity 38, February 21, 2013 ª2013 Eto express calpain-cleavable or calpain
cleavage-resistant forms of pro-IL-1a.
The remarkable finding of Zheng et al.
(2013) is that IL-1R2-mediated inhibition
of pro-IL-1a availability to processing by
calpain and other proteases, including
Granzyme B, elastase, and chymase,
can be relieved by caspase-1. Specifi-
cally, the authors showed that the addi-
tion of caspase-1 to IL-1R2 resulted in
the proteolytic processing of the latter
into two major products. Importantly,
upon cleavage of IL-1R2, it dissociated
from pro-IL-1a, which then became avail-
able to induce IL-1R1-dependent inflam-
mation either directly or after maturation
with calpain or other cellular proteases.
The designation of caspase-1 as a point
of control for functional IL-1a activation is
highly significant. Caspase-1 activation is
under the tight control of the inflamma-
somes that sense both DAMPs and
PAMPs in the cytosol (Schroder and
Tschopp, 2010). Currently acceptedlsevier Inc.concepts indicate that the
proinflammatory function of
inflammasomes is enabled
through caspase-1-depen-
dent proteolytic processing
of pro-forms of IL-1b and
IL-18, which, unlike a con-
stitutively expressed pro-IL-
1a, are inducible cytokines.
In the context of sterile in-
flammation, where IL-1b ex-
pression may not be induced
and only the ubiquitously
expressed pro-IL-1a is pres-
ent, inflammasome activa-
tion in response to noxious
metabolic or damage-derived
stimuli will lead to activation
of caspase-1, which will
target IL-1R2 for degradation
and release pro-IL-1a for
functional activation by a
second protease, calpain,
thus triggering local inflam-
matory response through IL-
1R1 (Figure 1).
This model linking IL-1R2
and caspase-1 to functional
activation of IL-1a may have
broad implications. This may
be the principal mechanism
that underlays the pathology
of numerous human diseases
where local and chronic
IL-1R1- and/or caspase-1-dependent inflammation leads to tissue
dysfunction in a sterile environment with-
out evident transcriptional IL-1b activa-
tion. Moreover, because ligation of the
Toll-like receptors leads to potent tran-
scriptional IL-1b activation and the
downstream signaling adaptors for IL-
1R1 and Toll-like receptors are the same
(Dinarello, 2009), inflammasome-depen-
dent licensing of functional activation of
IL-1a by ‘‘sterile’’ stimuli may lead to
pro-IL-1b production that will be followed
by its caspase-1-dependent processing
and release, thus leading to exacerbation
of inflammation. In this context, in
response to damage or noxious stimulus
assault, the initial proinflammatory IL-
1R1 signaling can be mediated by IL-1a,
while chronic inflammatory response
even without any pathogen presence
may then be sustained by both IL-1a
and IL-1b. Collectively, these data reveal
functional redundancy in mechanisms
of inflammasome-dependent activation
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responses. The relevance of these find-
ings to explain the mechanistic underpin-
ning for various pathological conditions
associated with sustained inflamma-
tion in humans now appears as amanage-
able challenge. Thus, what can make
necrosis ‘‘silent’’ by keeping a lid on
IL-1a? Now, the answer is clear—it is
IL-1R2.
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In this issue of Immunity, Cortez-Retamozo et al. (2013) demonstrate that the increased production of
angiotensin II in tumor-bearing mice induces the expansion of macrophage progenitors and the supply of
macrophages.Macrophages contribute to all facets of
tumor progression and thus are an impor-
tant component of the tumor microenvi-
ronment. Their role in tumor development,
angiogenesis, tumor cell invasion, and
metastases is well established (Qian and
Pollard, 2010) (Qian et al., 2011). For a
number of years, these cells have been
considered to be important negative
regulators of immune responses in cancer
(Mantovani and Sica, 2010) (Gabrilovich
et al., 2012). In a preclinical model, the
blockade of macrophage recruitment
improved the survival of mammary
tumor-bearing mice by slowing primary
tumor development and reducing pulmo-
nary metastasis (DeNardo et al., 2011).
There is now ample evidence demon-
strating that tumor-derived factors drive
an increased production of macrophages
in cancer. It is believed that different
growth factors, such as M-CSF (CSF-1),
play major roles in this process. In this
issue of Immunity, Cortez-Retamozo
et al. (2013) demonstrate that peptide
hormone angiotensine II (AngII) mightcontribute to the increased production of
macrophages in cancer by amplifying
self-renewing hematopoietic stem cells
and macrophage progenitors.
AngII is an oligopeptide that belongs to
the renin-angiotensin system, which regu-
lates blood pressure. Its precursor, angio-
tensin I (Ang I,) is derived from a2-globulin
angiotensinogen produced by the liver
after cleavage of a 10 amino acid peptide
by renin. Ang I is converted to AngII by the
angiotensin-converting enzyme (ACE).
Ang II acts as a hormone to affect blood
pressure via manymechanisms, including
cardiovascular, renal, adrenal, and other
systems. ACE inhibitors are major drugs
used in the treatment of high blood
pressure. Previous studies have demon-
strated that AngII might promote inflam-
mation and that it interacts with mono-
cytes and mobilizes these cells from the
splenic reservoir. In the current study,
Cortez-Retamozo et al. used a mouse
model of lung adenocarcinoma caused
by the activation of oncogene Kras and
inactivation of the tumor suppressorgene p53. These mice developed lung
cancer after an intranasal infection with
Cre-recombinase-containing adenovirus.
The authors found that tumor-bearing
mice had a significantly higher concentra-
tion of AngII in plasma than did control
mice. Treatment of naive mice with AngII
resulted in increased colony-forming
activity of splenocytes, suggesting that
AngII might have an effect on myelopoie-
sis. This conclusion was further sup-
ported by the fact that AngII-treated
mice had a higher proportion of myeloid
progenitors. The expansion of progenitor
cell numbers occurred in the spleen but
not in bone marrow. AngII is a potent
regulator of hemodynamics. Thus, it might
have an effect on cell mobilization and the
expansion of myeloid cell numbers. To
address this concern, Cortez-Retamozo
et al. used vasodilator hydralazine and
demonstrated that this did not affect the
AngII-inducible expansion of myeloid
progenitor cell numbers. Furthermore,
the effect of AngII on myeloid cells was
found to be mediated by its interactionFebruary 21, 2013 ª2013 Elsevier Inc. 205
